The invention belongs to the technical field of biological medicines, and particularly relates to application of
limonin in preparation of a
medicine for improving the left ventricular
diastolic function. The CAS number of the
limonin is 180-71-8, the molecular formula of the
limonin is C26H30O8, and the limonin in the
medicine is an effective component. Tests find that after
ejection fraction reserved
heart failure (HFpEF) model group mice are subjected to limonin high, medium and
low dose administration, compared with the model group without administration, the weight of the heart and
lung of the mice is remarkably reduced, left ventricular diastolic dysfunction and centripetal
cardiac hypertrophy of the mice can be remarkably improved, and the
curative effect of the mice is improved. Compared with the positive
drug empagliflozin, the
drug effect indexes have no obvious difference. Besides, HE and Masson
staining finds that compared with control group mice, obvious myocardial
interstitial fibrosis occurs in the model group mice, and
myocardial fibrosis can be obviously improved after limonin is high, medium and low and
empagliflozin is administrated.